· Published by Health Canada · Official notice
This is duplicated text of a letter from EMD Serono Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
June 11, 2009
Subject: Communication on the decision to withdraw Raptiva® in Canada
This Communication is to inform you about the decision for EMD Serono Canada Inc. to withdraw the market authorization of RAPTIVA in Canada.
EMD Serono Canada Inc., the company that markets RAPTIVA in Canada has in consultation with Health Canada decided to terminate the marketing of Raptiva (efalizumab) in Canada, due to safety concerns.
RAPTIVA was authorized in October 2005 for the treatment of plaque psoriasis in adult patients.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any occurrence of serious and/or unexpected adverse reactions in patients who received RAPTIVA should be reported to EMD Serono Canada Inc., or Health Canada at the following addresses:
EMD Serono Canada Inc.
2695 North Sheridan Way, Suite 200
Mississauga ON L5K 2N6
Telephone: 1-888-737-6668 x 5160
Fax: 905-919-0292
E-mail: drugsafetycanada@merckserono.net
Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 866-234-2345
Fax: 866-678-6789
CanadaVigilance@hc-sc.gc.ca
The Adverse Reaction Reporting Form and the Adverse Reaction Guidelines can be found on the Health Canada Web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions regarding the withdrawal of RAPTIVA, please call EMD Serono Canada Inc.’s Patient Services at 1-866-440-4245.
original signed by
Peter Grosser, Ph.D.
Director, Regulatory Affairs, Drug Safety & Medical Information
EMD Serono Canada Inc.